<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">691271</article-id><article-id pub-id-type="doi">10.18565/pharmateca.2025.5.129-134</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Pharmacological properties of drugs</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Фармакологические свойства лекарств</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Modern effective means of topical therapy and skin care for patients with psoriasis</article-title><trans-title-group xml:lang="ru"><trans-title>Современные эффективные средства топической терапии и ухода за кожей у больных псориазом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2872-3836</contrib-id><contrib-id contrib-id-type="spin">5878-4467</contrib-id><name-alternatives><name xml:lang="en"><surname>Filimonkova</surname><given-names>Nina N.</given-names></name><name xml:lang="ru"><surname>Филимонкова</surname><given-names>Нина Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Leading Researcher, Scientific and Clinical Department of Dermatology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, ведущий науч. сотр. научного клинического отдела дерматологии</p></bio><email>nnfil2008@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6353-6644</contrib-id><contrib-id contrib-id-type="spin">3470-9306</contrib-id><name-alternatives><name xml:lang="en"><surname>Kokhan</surname><given-names>Muza M.</given-names></name><name xml:lang="ru"><surname>Кохан</surname><given-names>Муза Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Scientific and Clinical Department of Dermatology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. научно-клиническим отделом дерматологии</p></bio><email>mkokhan@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Ural Research Institute of Dermatovenereology and Immunopathology</institution></aff><aff><institution xml:lang="ru">Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-09-24" publication-format="electronic"><day>24</day><month>09</month><year>2025</year></pub-date><volume>32</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>129</fpage><lpage>134</lpage><history><date date-type="received" iso-8601-date="2025-09-23"><day>23</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-09-23"><day>23</day><month>09</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО «Бионика Медиа»</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/691271">https://journals.eco-vector.com/2073-4034/article/view/691271</self-uri><abstract xml:lang="en"><p>The problem of topical therapy for patients with chronic dermatoses remains relevant in modern dermatology, despite a significant number of research works. The creation of new combined skin care products for patients with psoriasis allows potentiating the effect of most drugs in the absence of side effects in the form of allergic reactions, drug dependence and effects on other organs.</p> <p>Psoriasis in approximately 80% of patients manifests itself in a mild or moderate degree and is initially treated with local (topical) therapy. In the spectrum of topical therapy, glucocorticosteroids, betamethasone/calcipotriol, vitamin D3 analogues are effective.</p> <p>The domestic company Pharmtec has created a series of care products: Depsoriol<sup>®</sup> cream and lotion for patients suffering from vulgar psoriasis, including lesions of the scalp. In the study, when using this drug simultaneously with leading topical therapy products, or with subsequent care, a more rapid achievement of the clinical effect, positive dynamics of the psoriasis area and severity index (PASI) and the dermatological quality of life index (DQLI), compared with other skin care products, and the absence of side effects were noted.</p></abstract><trans-abstract xml:lang="ru"><p>Проблема топической терапии больных хроническими дерматозами остается актуальной в современной дерматологии, несмотря на значительное число исследовательских работ. Создание новых комбинированных средств ухода за кожей для больных псориазом позволяет потенцировать действие большинства лекарственных веществ при отсутствии побочных эффектов в виде аллергических реакций, лекарственной зависимости и воздействия на другие органы.</p> <p>Псориаз приблизительно у 80% пациентов проявляется в легкой или умеренно выраженной степени и первоначально подлежит лечению средствами местной (наружной) терапии. В спектре средств наружной терапии эффективны глюкокортикостероиды, бетаметазон/кальципотриол, аналоги витамина D3.</p> <p>Отечественной компанией «Фармтек» создана серия средств ухода: крем, лосьон Депсориол<sup>®</sup> (Depsoriol<sup>®</sup>) для пациентов, страдающих вульгарным псориазом, в том числе с поражением кожи волосистой части головы. В проведенном исследовании при использовании данного препарата одновременно с ведущими средствами топической терапии, либо при последующем уходе отмечено более быстрое достижение клинического эффекта, положительная динамика индекса тяжести псориатического процесса PASI и дерматологического индекса качества жизни (ДИКЖ), по сравнению с другими средствами по уходу за кожей, отсутствие побочных эффектов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>vitamin D3 analogues</kwd><kwd>Depsoriol</kwd><kwd>PASI and DQLI indices</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>аналоги витамина D3</kwd><kwd>Депсориол</kwd><kwd>индекс PASI и ДИКЖ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Олисова О.Ю., Бакулев А.Л., Кохан М.М. и др. К вопросу о классификации псориаза. 2021;97(5):18–25. [Olisova O.Yu., Bakulev A.L., Kokhan M.M., et al. Revisiting the question of psoriasis classification. 2021;97(5):18–25. (In Russ.)]. https://doi.org/10.25208/vdv1267</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Кубанов А.А., Богданова Е.В. Дермато-венерология в Российской Федерации: итоги 2023 г. Вестник дерматологии и венерологии. 2024;100(4):9–24. [Kubanov А.А., Bogdanova E.V. Dermatovenereology in the Russian Federation: results of 2023. Vestnik Dermatologii i Venerologii. 2024;100(4):9–24. (In Russ.)]. https://dx.doi.org/https://doi.org/10.25208/vdv16795</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Кунгуров Н.В., Филимонкова Н.Н., Тузанкина И.А. Псориатическая болезнь. Екатеринбург, 2002. 193 с. [Kungurov N.V., Filimonkova N.N., Tuzankina I.A. Psoriatic disease. Ekaterinburg, 2002. 193 p. (In Russ.)].</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Guilhou J.-J. Immunopathogenesis of psoriasis: news in an old concept. Dermatology. 1998;197:310–312.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Israel L., Mellett M. Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease. Front Immunol. 2018;9:2239. https://dx.doi.org/10.3389/fimmu.2018.02239</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mahil S.K., Twelves S., Farkas K., et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136:2251–2259. https://dx.doi.org/10.1016/j.jid.2016.06.618</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Cai Y., Xue F., Quan C., et al. A critical role of the IL-1β–IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2019;139:146–156. https://dx.doi.org/10.1016/j.jid.2018.07.025</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mikhaylov D., Hashim P.W., Nektalova T., Goldenberg G. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits. J Clin Aesthet Dermatol. 2019;12(6):46–54.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. https://dx.doi.org/10.1046/j.1365-2230.2001.00832.x</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Клинические рекомендации «Псориаз». Минздрав, 2023. [Clinical guidelines ‘Psoriasis’. RODVK 2023. (In Russ.)]. URL: https://cr.minzdrav.gov.ru</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Олисова О.Ю., Теплюк Н.П., Пинегин В.Б. Современные методы лечения псориаза. Русский медицинский журнал. 2015;9:483–484. [Olisova O.Yu., Teplyuk N.P., Pinegin V.B. Modern methods of psoriasis treatment. Russian Medical Journal. 2015;9:483–484. (In Russ.)].</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Makino T., Okajima K., Uebayashi R., Ohtake N., et al. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11β-hydroxysteroid dehydrogenase 2. Pharmacol Exp Ther. 2012;342(2):297–304. https://dx.doi.org/10.1124/jpet.111.190009</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Круглова Л.С. Турбовская С.Н. Кальципотриол – современные возможности длительного контроля над псориазом в течение года. Клиническая дерматология и венерология. 2017;16(2):53–59. [Kruglova L.S., Turbovskaya S.N. Calcipotriol – modern possibilities of long-term control over psoriasis during the year. Clinical dermatology and venereology. 2017;16(2):53–59. (In Russ.)]. https://dx.doi.org/10.17116/klinderma201716253-59</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Nazari S., Rameshrad M., Hosseinzadeh H. Toxicological effects of Glycyrrhiza glabra (Licorice): a review. Phytother Res. 2017;31(11):1635–1650. https://dx.doi.org/10.1002/ptr.5893</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Isbrucker R.A., Burdock G.A., Isbrucker R.A., Burdock G.A. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006;46(3):167–192. https://dx.doi.org/10.1016/j.yrtph.2006.06.002</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zhang Y., Wang Q., Sun S., Jiang L. The therapeutic effect of glycyrrhizic acid compound ointment on imiquimod-induced psoriasis-like disease in mice. PLoS One. 2023;18(8):e0290637. https://dx.doi.org/10.1371/journal.pone.0290637</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Piquero-Casals J., Morgado-Carrasco D., Granger C., et al. Urea in dermatology: a review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties. Dermatol Ther (Heidelb). 2021;11(6):1905–1915. https://dx.doi.org/10.1007/s13555-021-00611-y</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ковалева Ю.С., Кокина О.А., Ведлер А.А., Кожевникова П.Е. Возможности применения мочевины в дерматологии. Клиническая дерматология и венерология. 2020;19(5):685–689. [Kovaleva Ju.S., Kokina O.A., Vedler A.A., Kozhevnikova P.E. Urea applications in dermatology. Russian Journal of Clinical Dermatology and Venereology. 2020;19(5):685–689. (In Russ.)].</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Celleno L. Topical urea in skincare: a review. Dermatol Ther. 2018;31(6):e12690. doi: 10.1111/dth.12690</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Спиричев В.Б. Витамины, витаминоподобные и минеральные вещества: Справочник. М.: МЦФЭР, 2004. 240 с. [Spirichev V.B. Vitamins, vitamin-like and mineral substances: Handbook. M.: MCFER, 2004. 240 p. (In Russ.)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>van Rosendal S.P., Osborne M.A., Fassett R.G., Coombes J.S. Guidelines for glycerol use in hyperhydration and rehydration associated with exercise. Sports Med. 2010;40(2):113–119. https://dx.doi.org/10.2165/11530760-000000000-00000</mixed-citation></ref></ref-list></back></article>
